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Abstract
Background: The aim of this study was to determine the value of 18F-FDG uptake on screening PET/CT images for
the prediction of Helicobacter pylori (H. pylori) infection and chronic atrophic gastritis.
Methods: Among subjects who underwent 18F-FDG PET/CT for cancer screening from April 2005 to November
2015, PET/CT images were analyzed in 88 subjects who had gastrointestinal fiberscopy within 6 months. The
volumes of interest (VOIs) were placed in the fornix, corpus and antrum of the stomach to determine maximal
standardized uptake value (SUVmax) and mean SUV (SUVmean). Receiver operating characteristic curve (ROC)
analysis was performed to determine the diagnostic performance of SUV indicators in predicting H. pylori infection
and chronic atrophic gastritis.
Results: SUV indicators of the stomach were significantly higher in subjects with H. pylori infection than those
without (from P < 0.001 to P < 0.05). ROC analysis revealed that SUVmean had the highest performance in
predicting H. pylori infection (AUC 0.807) and chronic atrophic gastritis (AUC 0.784). SUVmean exhibited the
sensitivity of 86.5 % and the specificity of 70.6 % in predicting H. pylori infection, and the sensitivity of 75.0 % and
78.6 % in predicting chronic atrophic gastritis.
Conclusion: Assessment of 18F-FDG uptake in the stomach reflecting active inflammation is useful in predicting
patients with H. pylori infection and subsequent chronic atrophic gastritis which is closely associated with the risk of
gastric neoplasms.
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Background
Helicobacter pylori (H. pylori) infection is strongly re-
lated with many gastroduodenal diseases including
peptic ulcer diseases, chronic atrophic gastritis, mucosa
associated lymphoid tissue (MALT) lymphoma and
gastric cancer [1, 2]. In particular, gastric cancer is the
third most common of all cancers among males and the
fifth most common among females. Once infection of
H. pylori is established, it usually lasts for life and
exhibits carcinogenicity which induces gastric cancer
through chronic atrophic gastritis [3].
18F-FDG PET/CT is widely used in cancer staging and
cancer screening. However, previous studies demon-
strated that the sensitivity of 18F-FDG-PET in screening
gastric cancer in asymptomatic subjects was limited,
ranging from 10 % to 38 % [4, 5]. The main difficulty in
18F-FDG-PET diagnosis of gastric cancer is attributed to
physiological uptake of 18F-FDG in the stomach [6–10].
In addition to the abnormal 18F-FDG uptake associated
to malignant tumors, physiological or inflammation re-
lated uptakes are seen on 18F-FDG PET images. Takaha-
shi et al [11] evaluated the pattern of 18F-FDG uptake in
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the stomach in association with endoscopic findings of
the gastric mucosa in 272 cases and found that accumu-
lation pattern of 18F-FDG largely corresponds to the
presence of mucosal inflammation. Although semi-
quantitative evaluation of 18F-FDG uptake using stan-
dardized uptake values (SUVs) in the stomach has been
used for assessing MALT lymphoma [12], differentiating
malignant and benign gastric diseases [13] and predict-
ing the prognosis of gastric carcinoma [14], the value of
SUV measurement of FDG uptake for detecting H. pyl-
ori infection and subsequent chronic atrophic gastritis
has not been well established. Lin et al [15] found a sig-
nificant positive correlation between SUVs of 18F-FDG
in the stomach and the values of C-13 urea breath test
which is the most commonly used noninvasive test for
H. pylori. However, the number of the subjects was lim-
ited (n = 16) and endoscopic examination was not per-
formed in their study.
Consequently, the aim of this study was to investigate
the value of semi-quantitative assessment of 18FDG up-
take in the stomach with SUV for predicting H. pylori
infection and chronic gastritis in subjects who under-
went 18F-FDG PET/CT for cancer screening.
Methods
Subjects
Medical records of subjects who underwent 18F-FDG
PET/CT for cancer screening between April 2005 and
November 2015 were retrospectively investigated.
Among them, 88 subjects underwent gastrointestinal
fiberscopy within 6 months of the PET/CT study. The
reasons for gastrointestinal fiberscopy were increased
uptake of 18F-FDG in the stomach (55 subjects), previ-
ous history of peptic ulcer (5 subjects), familial history
of peptic ulcer or gastric cancer (4 subjects), or request
by the examinee (32 subjects). None of these 88 subjects
had a previous history of gastric cancer or MALT
lymphoma. The presence or absence of H. pylori infec-
tion, as well as the diagnosis of chronic atrophic gastri-
tis, were determined in the medical records in all 88
subjects who underwent gastrointestinal fiberscopy.
Thus, 18F-FDG PET/CT images were evaluated in these
88 subjects. This retrospective study was approved by
the institutional review board of Mie University Hospital
(study no. 2989) and was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice.
Informed consent was waived for this retrospective
study.
PET/CT imaging
All subjects fasted for at least 6 h before PET/CT acqui-
sitions. Prior to 18F-FDG injection, blood glucose levels
were determined from capillary blood samples and were
confirmed to be less than 150 mg/dl in all subjects. A
3.7-MBq/kg dose of 18F-FDG was injected intravenously
in one arm. PET/CT was performed by using an Aqui-
duo PCA-700B scanner (Toshiba, Nasu, Japan) or Dis-
covery PET/CT 690 scanner (GE, Milwaukee, WI).
Images from the skull to the mid-thigh were acquired
approximately 60 min after 18F-FDG injection, by
employing 3-dimentional acquisitions in 7-9 bed posi-
tions with 2-min acquisition in each position. Subjects
were placed supine with the arms alongside the body or
lifted up to the skull and were allowed to breathe nor-
mally during PET acquisitions. CT images acquired in
approximately ten seconds during a natural breath-
holding were used for attenuation correlation and gener-
ation of fusion images. Attenuation-corrected PET im-
ages with co-registered CT data were reviewed.
PET/CT image analysis
18F-FDG uptake in the stomach was measured semi-
quantitatively by placing volumes of interest (VOIs) at
the fornix, corpus and antrum of the stomach as well as
in the liver by consensus of two observers. The VOIs
were 3D spheres and the size of VOIs were 5 mm in
diameter for the stomach, and 30 mm in diameter for
the liver. The VOI for the stomach was carefully placed
in the gastric wall by monitoring both PET-CT fusion
images and PET images. VOI for the liver was placed to
avoid the region just blow the diaphragm for preventing
the motion blurring artifact. For each VOI, maximal
SUV (SUVmax) and mean SUV (SUVmean) were re-
corded (Fig. 1). ROC analysis was performed for several
different SUV indicators. Maximum SUVmax and mean
SUVmax were the maximum and mean values of the
SUVmax measured at the fornix, corpus and antrum.
Maximum SUVmean and mean SUVmean were the
maximum and mean values of the SUVmean measured
at the fornix, corpus and antrum. In addition, maximum
SUVmax / SUVmean liver, mean SUVmax /SUVmean
liver, maximum SUVmean / SUVmean liver and mean
SUVmean / SUVmean liver were determined to evaluate
the diagnostic performance of these indicators in pre-
dicting H pylori infection and chronic atrophic gastritis.
Statistical analysis
SPSS version 22.0 software (IBM Japan, Tokyo, Japan)
was used for statistical analyses. We determined whether
statistically significance difference was observed in SUVs
of the stomach between those with and without H. pyl-
ori, and those with and without chronic atrophic gastri-
tis. The sensitivity and specificity of SUV indicators in
predicting H. pylori infection and chronic atrophic gas-
tritis were calculated by using an optimal cut-off point
on the ROC curve that has the minimum distance to the
upper left corner (where sensitivity = 1 and specificity =
1). The statistically significance was evaluated by Mann-
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Whitney U-test or Wilcoxon rank sum test. All analysis




Characteristics of the subjects including laboratory diag-
nosis by gastrointestinal fiberscopy are shown in Table 1.
Diagnosis of H. pylori infection was made by a rapid
urease test, a stool antigen test and an information of
previous medical institution or prevention center. Three
subjects who had chronic atrophic gastritis without H.
pylori infection on medical records in previous medical
institutions, were turned out to be H. pylori positive by
further investigation in our hospital.
PET/CT image analysis
Table 2 summarizes the SUVmax and SUVmean of
18 F-FDG uptake at the fornix, corpus and antrum, as
well as the maximum and the mean values of SUVmax
and SUVmean at 3 regions in the stomach in associated
with H. pylori infection. Table 3 summarizes these SUV
indicators in associated with chronic atrophic gastritis.
All of these SUV indicators in the stomach were signifi-
cantly higher in patients with H. pylori infection than in
those without H. pylori (P < 0.001). In addition, all of
these SUV indicators were significantly higher in
patients with chronic atrophic gastritis than in those
without chronic atrophic gastritis (P < 0.001). It was also
noted that the 18 F-FDG uptake of the fornix in the
stomach was significantly higher than those in corpus
and antrum, independent of the presence of H. pylori in-
fection and chronic atrophic gastritis.
Diagnostic performance by ROC analysis
Figure 2 shows ROC curves for SUV indicators in pre-
dicting H. pylori infection and chronic atrophic gastritis.
In Table 4, the area under ROC curves, the optimal cut-
off values, the sensitivities and specificities in predicting
H. pylori infection and chronic atrophic gastritis are pre-
sented. All of SUV indicators demonstrated good diag-
nostic performance for the prediction of H. pylori
infection and chronic atrophic gastritis. Among these 4
SUV indicators, mean SUVmean exhibited the highest
area under ROC curves for predicting H. pylori infection
(0.807, 95%CI 0.715 – 0.898) and for chronic gastritis
(0.784, 95 % CI 0.684 – 0.884). As shown in Table 5,
normalization of these SUV indicators in the stomach by
the liver SUV did not improve the area under ROC
curves for the diagnosis of H. pylori infection. For pre-
dicting chronic atrophic gastritis, normalization of SUV
indicators by the liver SUV slightly improve the area
under ROC curves, with the highest area under ROC










Fig. 1 The methods for measuring 18F-FDG uptake of the stomach and the liver. VOIs of 3D sphere were placed at the fornix, corpus and antrum
of the stomach and the liver in each subject. SUVmax (shown as Max SUV-bw on MIP, fusion images and PET images) and SUVmean were deter-
mined in each VOI in the stomach, and SUVmean liver was determined in liver VOI. a A MIP image of a subject with H. pylori infection, VOI was
placed to avoid the area just blow the diaphragm for preventing the motion blurring artifact. The VOIs were placed by monitoring both PET/CT
fusion images and PET images. b-1, 2 VOI of the liver. c1, 2 VOI of gastric fornix. d-1, 2 VOI of gastric corpus. e-1, 2 VOI of gastric antrum
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SUVmax. However, the amount of improvement with
normalization by the liver SUV was quite limited.
Dot plots of mean SUVmean in subjects with and
without H. pylori infection and in those with and with-
out chronic gastritis were shown on Fig. 3. The sensitiv-
ity and specificity of mean SUVmean were 86.5 % and
70.6 % for H. pylori infection (optimal cut-off value of
2.66), and 75.0 % and 78.6 % for chronic gastritis (opti-
mal cut-off value of 2.57), respectively.
Gastric neoplasms found by GIF
Among the 88 subjects, seven neoplasms were found on
gastrointestinal fiberscopy, including four early gastric
cancers, two gastric adenomas and a MALT lymphoma.
In four gastric cancer and two gastric adenomas, no
focal increase in 18F-FDG uptake corresponding to tu-
mors was observed, while H. pylori was positive in these
cases. In a patient with MALT lymphoma, the antibody
test of H. pylori was negative and increased focal 18F-
FDG uptake at gastric corpus was detected which corre-
sponded to MALT lymphoma proven by gastrointestinal
fiberscopy. The infection of H. pylori was also demon-
strated by histologic specimen taken by fiberscopy.
Discussion
In the current study, we investigated the value of 18 F-
FDG uptake measured by SUV on screening PET/CT
images for the prediction of H. pylori infection and
chronic atrophic gastritis determined by gastrointestinal
fiberscopy. The major findings in this study were [1]
The SUV of 18 F-FDG uptake in the stomach was sig-
nificantly elevated in patients with H. pylori infection
and in those with chronic atrophic gastritis [2]; 18 F-
Table 1 Characteristics of the subjects
Age (y)
Mean ± SD 58 ± 11




H. Pylori infection Number (%)
Positive 37 (42.0)
Negative 51 (58.0)
Chronic atrophic gastritis Number (%)
Positive (H. Pylori positive) 37 (40.9)
(H. Pylori negative) 24 (27.3)
Negative 27 (31.8)
Neoplasms (finding on fiberscopy) Number
Early gastric cancer (H. Pylori positive) 4
Gastric adenoma (H. Pylori positive) 2
MALT lymphoma (H. Pylori positive) 1
Other fiberscopic findings 3
Superficial gastritis (H. Pylori positive) 3
(H. Pylori negative) 2
Erosive gastritis (H. Pylori positive) 2
(H. Pylori negative) 3
Gastric ulcer scar (H. Pylori positive) 1
Duodenal ulcer scar (H. Pylori positive) 1
Erosion of E-C Junction (H. Pylori negative) 1
Reflux esophagitis (H. Pylori positive) 1
(H. Pylori negative) 1
Table 2 The SUVs of 18 F-FDG in the stomach in associated
with Helicobacter pylori infection
H. pylori(+) N = 37 H. pylori(-) N = 51
SUVmax (mean ± SD)
Fornix 4.01 ± 0.80 3.38 ± 0.97++
Corpus 3.70 ± 0.95** 2.71 ± 0.90*+
Antrum 3.58 ± 1.12*** 2.68 ± 0.99*+
Maximum 4.36 ± 0.88 3.57 ± 1.01
Mean 3.76 ± 0.78 2.93 ± 0.80+
SUVmean (mean ± SD)
Fornix 3.62 ± 0.71 3.06 ± 0.90++
Corpus 3.31 ± 0.87*** 2.39 ± 0.83*+
Antrum 3.06 ± 0.96** 2.30 ± 0.87*+
Maximum 3.90 ± 0.74 3.19 ± 0.92+
Mean 3.33 ± 0.67 2.58 ± 0.73+
Significant difference between each region and fornix at same group (*P < 0.001,
**P < 0.01, ***P < 0.05)
Significant difference between H. Pylori (+) and H. Pylori (-) at same region
(+P < 0.001, ++P < 0.01, +++P < 0.05)
Table 3 The SUVs of 18 F-FDG in the stomach in associated
with chronic gastritis
Chr Gastritis(+) N = 60 Chr Gastritis(-) N = 28
SUVmax (mean ± SD)
Fornix 3.86 ± 0.91 3.20 ± 0.92+
Corpus 3.39 ± 1.00* 2.57 ± 0.92*+
Antrum 3.37 ± 1.19** 2.39 ± 0.67*+
Maximum 4.12 ± 0.97 3.42 ± 1.02++
Mean 3.54 ± 0.89 2.72 ± 0.62+
SUVmean (mean ± SD)
Fornix 3.49 ± 0.85 2.88 ± 0.80+++
Corpus 3.02 ± 0.94* 2.25 ± 0.81*+
Antrum 2.88 ± 1.01* 2.06 ± 0.65*+
Maximum 3.69 ± 0.88 3.06 ± 0.90++
Mean 3.13 ± 0.79 2.40 ± 0.55+
Significant difference between each region and fornix at same group
(*P < 0.001, **P < 0.01)
Significant difference between Chr Gastritis (+) and Chr Gastritis (-) at same
region (+ P < 0.001, ++ P <0.01, +++ P < 0.05)
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FDG uptake of the fornix in the stomach was signifi-
cantly higher than those in corpus and antrum regard-
less of H. pylori infection and chronic atrophic gastritis
[3]; mean SUVmean showed the highest area under
ROC curves for predicting H. pylori infection (0.807)
and chronic atrophic gastritis (0.784), and is useful for
identifying patients who require gastrointestinal fiber-
scopy. Normalization of stomach SUVs by liver SUV
provided minimal differences in the diagnostic perform-
ance and is not considered to be necessary.
Accumulation of 18F-FDG in the stomach
Pattern of accumulation of 18F-FDG in the stomach and
its associated with endoscopic findings of the gastric
mucosa and H. pylori infection were previously investi-
gated by Takahashi et al [11] by using a visual assess-
ment of 18F-FDG PET image. They classified 18F-FDG
uptake in the stomach into three groups (A: localized ac-
cumulation in the fornix, B: diffuse accumulation
throughout the entire stomach, C: no accumulation).
They found that H. pylori infections were more frequent
in Groups A and B than in Group C, concluding that ac-
cumulation of 18F-FDG in the stomach suggests a high
probability of inflammatory changes to the gastric mu-
cosa, forming a background for the development of can-
cer or malignant lymphoma. In our current study, we
used a more objective approach by measuring SUVs of
18F-FDG in the fornix, corpus and antrum. Consistent
with previous report [8, 11], we found that 18F-FDG up-
take of the fornix was significantly higher than corpus
and antrum. In addition, SUV of 18F-FDG in the fornix
was significantly higher than those in corpus and an-
trum, not only in the subjects with H. pylori infection
and chronic atrophic gastritis, but also in those without
H. pylori infection or chronic atrophic gastritis, suggest-
ing that high 18F-FDG uptake in an oral side of the
stomach is physiological. We also noticed that H. pylori
infection and chronic atrophic gastritis are associated
with elevated SUVs in all gastric regions including the
fornix, corpus and antrum. This indicates that H. pylori
A B
Fig. 2 ROC curves for SUV indicators. a ROC curves for predicting H. pylori infection. b ROC curves for predicting chronic atrophic gastritis.
Among these SUV indicators, the highest diagnostic performance was achieved with the mean SUVmean in the fornix, corpus and antrum for
predicting H. pylori infection as well as for predicting chronic atrophic gastritis
Table 4 Diagnostic performance of SUVs for H. pylori infection
Predictive Indicators AUC Cut-off Sensitivity Specificity 95 % CI of AUC P value
Maximun SUVmax 0.738 3.66 81.1 % 60.8 % 0.635 – 0.841 <0.001
Mean SUVmax 0.793 3.11 81.1 % 72.5 % 0.699 – 0.887 < 0.001
Maximun SUVmean 0.739 3.30 81.1 % 62.7 % 0.636 – 0.841 < 0.001
Mean SUVmean 0.807 2.66 86.5 % 70.6 % 0.715 – 0.898 < 0.001
Diagnostic performance of SUVs for chronic atrophic gastritis
Maximun SUVmax 0.708 3.42 76.7 % 60.7 % 0.585 – 0.831 0.02
Mean SUVmax 0.773 2.86 76.7 % 67.9 % 0.671 – 0.875 < 0.001
Maximun SUVmean 0.709 3.15 75.0 % 64.3 % 0.585 – 0.833 0.02
Mean SUVmean 0.784 2.57 75.0 % 78.6 % 0.684 – 0.884 < 0.001
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infection causes increased 18F-FDG uptake reflecting ac-
tive inflammation throughout the entire stomach.
Detection of gastric neoplasms by 18F-FDG PET/CT
For the assessment of patients with advanced gastric cancer,
18F-FDG PET/CT has been shown to be useful in detecting
nodal metastasis and distant metastasis, and in predicting
prognosis [16–20]. However, 18F-FDG PET/CT is not useful
for screening gastric cancers [5, 11, 21, 22]. Shoda et al.
studies 2861 asymptomatic subjects and found that the sen-
sitivity of 18F-FDG PET for gastric cancer was as low as
10 % [3]. Consequently the use of gastrointestinal fiberscopy
is considered more appropriate in screening gastric cancer.
Clinical implications
Our results demonstrated that semi-quantitative assess-
ment of 18F-FDG uptake with SUV has high diagnostic ac-
curacy in predicting H. pylori infection and chronic
atrophic gastritis. As previously mentioned, H. pylori in-
fection and subsequent chronic atrophic gastritis lead to
increased risk of gastric cancer formation. Inflammatory
change in the gastric mucosa caused by H. pylori forms a
background for the development of gastric cancer or ma-
lignant lymphoma. In a Japanese cohort study, the popula-
tion attributable fraction (PAF) of H. pylori infection for
gastric cancer incidence (i.e. the fraction of gastric cancer
incident cases that is attributable to H. pylori infection)
was estimated to be 84 % [3]. Despite the declined preva-
lence of H. pylori infection for the past 30 years, gastric
cancer is the second most frequent cause of cancer death
in both males and females in Japan, and the most frequent
cancer in males and the second most frequent cancer in
females [23]. Therefore, gastrointestinal fiberscopy should
be strongly recommended for subjects with increased 18F-
FDG uptake in the stomach. According to the results in
this study, high area under ROC of 0.807 and high sensi-
tivity of 86.5 % can be achieved when mean SUVmean
values of > 2.66 was used as a threshold.
Limitations
Several limitations must be acknowledged in this study.
First, this is a single-center study with a limited number
Table 5 Diagnostic performance of SUVs normalized by SUV in the liver for H. Pylori infection
Predictive Indicators AUC Cut-off Sensitivity Specificity 95 % CI of AUC P value
Maximun SUVmax 0.739 1.64 64.9 % 72.5 % 0.637 – 0.841 <0.001
Mean SUVmax 0.796 1.31 81.1 % 74.5 % 0.700 – 0.892 <0.001
Maximum SUVmean 0.738 1.37 83.8 % 60.8 % 0.635 – 0.841 <0.001
Mean SUVmean 0.791 1.15 81.1 % 72.5 % 0.695 – 0.887 <0.001
Diagnostic performance of SUVs normalized by SUV in the liver for chronic atrophic gastritis
Maximun SUVmax 0.721 1.44 73.3 % 60.7 % 0.596 – 0.847 0.01
Mean SUVmax 0.793 1.25 76.7 % 78.6 % 0.686 – 0.900 <0.001
Maximum SUVmean 0.711 1.25 83.3 % 60.7 % 0.583 – 0.838 0.02
Mean SUVmean 0.790 1.09 78.3 % 75.0 % 0.682 – 0.897 <0.001
A B
Fig. 3 Distribution of mean SUVmean values. a Dot plots for mean SUVmean values in subjects with and without H. pylori infection. b Dot plots
for mean SUVmean values in subjects with and without chronic atrophic gastritis. Statistical significant difference for the mean SUVmean values
was observed between subjects with and without H. pylori infection (p < 0.001) and between subjects with and without chronic
gastritis (p < 0.001)
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of subjects, and there is a selection bias for subjects who
underwent gastrointestinal fiberscopy. Second, the de-
gree of chronic atrophic gastritis was not evaluated in
current study, because the laboratory diagnosis by
gastrointestinal fiberscopy was qualitative and operator-
dependent. Third, CT images were acquired during nat-
ural breath-holding while PET images were obtained
during free-breathing. This may result in misregistration
artifact and alteration in SUV. Forth, SUV of 18F-FDG
uptake in the stomach was not compared with the
gastrointestinal fiberscopy findings in detail. Further in-
vestigation by prospective multi-center study using both
PET-CT and gastrointestinal fiberscopy is necessary to
determine the value of 18F-FDG PET in early detection
and prevention of gastric cancer.
Conclusion
Uptake of 18F-FDG in the stomach reflecting active in-
flammation is strongly associated with H. pylori infection
and subsequent chronic atrophic gastritis. Subjects dem-
onstrating increased SUV of 18F-FDG uptake in the
stomach should be recognized as patients with high like-
lihood H. pylori infection and at increased risk of gastric
neoplasms. Gastrointestinal fiberscopy should be recom-
mended in these subjects.
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